Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
- 11 October 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (12), 1109-1117
- https://doi.org/10.1016/s1470-2045(11)70244-3
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerGynecologic Oncology, 2011
- Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor AngiogenesisMolecular Therapy, 2010
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2010
- Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Aflibercept in Epithelial Ovarian CarcinomaFuture Oncology, 2009
- Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case SeriesClinical Breast Cancer, 2009
- Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnti-Cancer Drugs, 2008
- Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer ModelClinical Cancer Research, 2005
- Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?Anti-Cancer Drugs, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000